Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2018 > U.S. FDA approves Lilly migraine drug; price same as rivals

U.S. FDA approves Lilly migraine drug; price same as rivals

Read also

Astellas withdraws Europe ACP application for AMD treatment

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...

Social media engagement boosts rare disease outreach

Social media engagement boosts rare disease outreach

Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at Andarix Pharmaceuticals, a biotech developing targeted oncology therapies.

Pharma companies must adapt to keep pace with AI developments, say experts

Pharma companies must adapt to keep pace with AI developments, say experts

At the Outsourcing in Clinical Trials Conference, key opinion leaders shared predictions for workflow changes due to AI.